


PointCare NOW Comparison to BD FACSCalibur at CDC in 2010

In early 2010, the U.S. Centers for Disease Control and Prevention (CDC) carried out an independent performance study in Atlanta. Thirty four (34) samples were tested on a PointCare NOW instrument and on a Becton Dickenson FACSCalibur instrument with TRI-Test reagents as the in-house predicate system. Replicate precision in whole blood and control samples was also compared at CDC. These independently acquired data were shared with PointCare Technologies and are shown here. The CDC study did not include samples from HIV+ patients and as a result excludes CD4 counts below 400 cells/ μ L. The results shown below incorporate data from 9 HIV+ samples with low CD4 counts tested on the same platforms in Ottawa by Health Canada in 2010.



Bland Altman Summary PointCare NOW vs. FACSCalibur				
	CD4		CD4%	
	Absolute Units	As %	Absolute Units	As %
Bias	10/ μ L	1.5%	-0.2%	-0.3%
SD	42/ μ L	10%	3%	10%
Range	139/ μ L – 1,498/ μ L		12% - 59%	

Source: Combined data from CDC and Health Canada 2010

Precision Summary using Ten Replicates (%CV)		
Sample	PointCare	FACSCalibur
Whole Blood ~700/ μ L	6.7%	5.4%
Whole Blood ~1,100/ μ L	5.1%	4.5%
Whole Blood ~1,100/ μ L	5.1%	3.7%
Whole Blood ~1,300/ μ L	5.8%	5.1%
Whole Blood ~1,400/ μ L	3.8%	4.6%
Control ~200/ μ L	7.1%	--
Control ~700/ μ L	3.8%	--

Source: CDC Study 2010 (whole blood) and PointCare Technologies (controls)